BR112012014689A2 - composição de vacina - Google Patents

composição de vacina

Info

Publication number
BR112012014689A2
BR112012014689A2 BR112012014689A BR112012014689A BR112012014689A2 BR 112012014689 A2 BR112012014689 A2 BR 112012014689A2 BR 112012014689 A BR112012014689 A BR 112012014689A BR 112012014689 A BR112012014689 A BR 112012014689A BR 112012014689 A2 BR112012014689 A2 BR 112012014689A2
Authority
BR
Brazil
Prior art keywords
vaccine composition
formulations
immunogenic
adjuvant
allow
Prior art date
Application number
BR112012014689A
Other languages
English (en)
Other versions
BR112012014689B1 (pt
Inventor
Gairola Sunil Jagdishprasad
Gautam Manish Maheshkumar
Jadhav Suresh Sakharam
Original Assignee
Serum Inst India Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Inst India Ltd filed Critical Serum Inst India Ltd
Publication of BR112012014689A2 publication Critical patent/BR112012014689A2/pt
Publication of BR112012014689B1 publication Critical patent/BR112012014689B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

patente de invenção: composição de vacina. a presente invenção formulações eficazes em relação ao custo e ipv imunogênicas. as ditas formulações contêm uma adjuvante que pode permitir uma redução da dose de 5 a 10 vezes para as vacinas contra vírus da pólio inativadas.
BR112012014689-0A 2009-12-16 2010-12-16 composição imunogênica BR112012014689B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2911MU2009 2009-12-16
PCT/IN2010/000814 WO2011074006A2 (en) 2009-12-16 2010-12-16 Vaccine composition

Publications (2)

Publication Number Publication Date
BR112012014689A2 true BR112012014689A2 (pt) 2016-04-05
BR112012014689B1 BR112012014689B1 (pt) 2019-11-12

Family

ID=44167787

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012014689-0A BR112012014689B1 (pt) 2009-12-16 2010-12-16 composição imunogênica

Country Status (3)

Country Link
CN (1) CN102655879B (pt)
BR (1) BR112012014689B1 (pt)
WO (1) WO2011074006A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016063291A1 (en) * 2014-10-07 2016-04-28 Serum Institute Of India Private Limited Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
US11793869B2 (en) * 2014-10-07 2023-10-24 Serum Institute Of India Pvt Ltd. Methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
CN106290886A (zh) * 2016-07-28 2017-01-04 北京科兴生物制品有限公司 一种检测ⅲ型脊髓灰质炎病毒d抗原含量的方法
CN108387726A (zh) * 2018-01-13 2018-08-10 中国医学科学院医学生物学研究所 脊髓灰质炎病毒ⅰ、ⅱ、ⅲ型d抗原同步快速鉴别、定量检测方法及其检测试剂盒和应用
CN108241058A (zh) * 2018-01-13 2018-07-03 中国医学科学院医学生物学研究所 一种脊髓灰质炎病毒ⅲ型d抗原预包被检测方法及其检测试剂盒和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
GB0405787D0 (en) * 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
EP1645283A1 (en) * 2004-10-08 2006-04-12 Chiron Behring GmbH & Co. KG Combination vaccine

Also Published As

Publication number Publication date
WO2011074006A4 (en) 2012-01-05
WO2011074006A3 (en) 2011-11-17
CN102655879B (zh) 2016-03-09
WO2011074006A2 (en) 2011-06-23
BR112012014689B1 (pt) 2019-11-12
CN102655879A (zh) 2012-09-05

Similar Documents

Publication Publication Date Title
CO6331297A2 (es) Composiciones adyuvantes novedosas
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
BR112013006396A2 (pt) composições imunogênicas
CL2007001698A1 (es) Composicion inmunogenica que comprende los lipooligosacaridos meningococicos (los) de inmunotipos l2 y l3 de cepas neissericas; composicion de vacuna que la comprende; procedimiento de preparacion; y su uso para la prevencion o tratamiento de enfermedades causadas por uno o mas serogrupos de n. meningitidis.
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
BR112015005056A2 (pt) vacinas de combinação com sorogrupo b meningococcus e d/t/p
BRPI0813307B8 (pt) composição imunogênica, vacina, e, processo para fabricar a vacina
IN2012DN02736A (pt)
BR112013005329A2 (pt) variantes não lipidadas de antígenos orf2086 de neisseria meningitidis
BR112015001313A2 (pt) composições de vacina
CO6321162A2 (es) Una vacuna que comprende una cantidad inmunogenica de un antigeno en somastatina y un adyuvante
BR112013000776A2 (pt) método e formulação para tratamento de deficiência de ácido siálico
UA100370C2 (uk) Спосіб вакцинації птахів проти salmonella
BR112012004698A2 (pt) métodos de redução de atividade virucida em composições de pcv-2 e composições de pcv-2 com uma imonugenicidade aprimorada.
CO6361948A2 (es) Uso de antigeno de mycoplasma bovis
BR112012014689A2 (pt) composição de vacina
GB2539148A (en) Vaccine compositions
BR112021001188A8 (pt) Composição que contém vacina contra a influenza
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
BR112012024708A2 (pt) composição de compostos orgânicos
TN2012000217A1 (en) The use of an l3 and/or l5 source as a vaccine or as a diagnostic for a parasitic disease
BR112012012921A2 (pt) uso de uma quantidade imunogênica de um vírus da doença de newcastle inativado e um adjuvante, composição farmacêutica, e, kit de partes
AR065362A1 (es) Utilizacion de lactobacillus casei para reforzar la proteccion inducida por la vacunacion antigripal
BR112013003064A2 (pt) agente profilático ou terapêutico para a esteato-hepatite não alcoólica
BR112013023354A2 (pt) vacina para rinite equina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25D Requested change of name of applicant approved

Owner name: SERUM INSTITUTE OF INDIA PRIVATE LIMITED (IN)

B06T Formal requirements before examination
B06T Formal requirements before examination
B06I Technical and formal requirements: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 6.20 NA RPI NO 2529 DE 25/06/2019 POR TER SIDO INDEVIDA.

B09A Decision: intention to grant
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/12/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/12/2010, OBSERVADAS AS CONDICOES LEGAIS